The alphavaccine technology is based on AlphaVax’s proprietary replicon vector platform derived from attenuated strains of the alphavirus, Venezuelan equine encephalitis (VEE) virus. Industry interest in the alphavaccine technology has increased as vaccine candidates move through the development pipeline.
The alphavaccine technology is based on AlphaVax’s proprietary replicon vector platform derived from attenuated strains of the alphavirus, Venezuelan equine encephalitis (VEE) virus. Industry interest in the alphavaccine technology has increased as vaccine candidates move through the development pipeline.
The alphavaccine technology is based on AlphaVax’s proprietary replicon vector platform derived from attenuated strains of the alphavirus, Venezuelan equine encephalitis (VEE) virus. Industry interest in the alphavaccine technology has increased as vaccine candidates move through the development pipeline.
The alphavaccine technology is based on AlphaVax’s proprietary replicon vector platform derived from attenuated strains of the alphavirus, Venezuelan equine encephalitis (VEE) virus. Industry interest in the alphavaccine technology has increased as vaccine candidates move through the development pipeline.
The alphavaccine technology is based on AlphaVax’s proprietary replicon vector platform derived from attenuated strains of the alphavirus, Venezuelan equine encephalitis (VEE) virus. Industry interest in the alphavaccine technology has increased as vaccine candidates move through the development pipeline.